Renal prostacyclin influences renal function in non-azotemic cirrhotic patients treated with furosemide.
The influence of prostaglandins on renal function changes induced by furosemide was analyzed in 21 non-azotemic cirrhotic patients with ascites. Patients were studied in two periods of 120 min immediately before and after furosemide infusion (20 mg, ev). Furosemide caused an increase in creatinine clearance in 15 patients (group A: 99 +/- 7 vs. 129 +/- 5 ml/min; mean +/- S.E.) and a reduction in the remaining six (group B: 102 +/- 13 vs. 71 +/- 9 ml/min). Parallel changes were observed in the urinary excretion of 6-Keto-prostaglandin-F1 alpha (metabolite of renal prostacyclin) which augmented after furosemide in 14 of the 15 patients from group A (478 +/- 107 vs. 1034 +/- 159 pg/min, p less than 0.001) and decreased in all patients from group B (1032 +/- 240 vs. 548 +/- 136 pg/min, p less than 0.05). In contrast, the urinary excretion of prostaglandin E2 was stimulated by furosemide in all patients (group A, 92 +/- 19 vs. 448 +/- 60 pg/min, p less than 0.001; and group B, 209 +/- 63 vs. 361 +/- 25 pg/min, p less than 0.05). In all of the patients furosemide-induced changes (post- minus pre-furosemide values) in creatinine clearance were closely correlated in a direct and linear fashion with those in 6-Keto-prostaglandin-F1 alpha (r = 0.74; p less than 0.001). These changes were associated with a higher furosemide-induced natriuresis in group A than in group B (641 +/- 68 vs. 302 +/- 46 mumol/min, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Quiroga
J
J
Department of Internal Medicine, University Clinic of Navarra, Pamplona, Spain.
Zozaya
J M
JM
Labarga
P
P
Rodríguez-Ortigosa
C M
CM
Milazzo
A
A
Prieto
J
J
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D015232:Dinoprostone / Q000652:urine; D011464:Epoprostenol / Q000502:physiology*; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D014511:Uremia / Q000209:etiology
D015121:6-Ketoprostaglandin F1 alpha; D005665:Furosemide; D011464:Epoprostenol; D015232:Dinoprostone